Secretory IgA specific for MPER can protect from HIV-1 infection in vitro

AIDS

Volumn 27, Issue 12, 2013, Pages 1992-1995

  Benjelloun, Fahd ^a   Dawood, Reham ^a   Urcuqui Inchima, Silvio ^b   Rochereau, Nicolas ^a   Chanut, Blandine ^a   Verrier, Bernard ^c   Lucht, Frederic ^a   Genin, Christain ^a   Paul, Stéphane ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN M;

ANTIBODY SPECIFICITY; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; MALE; SALIVA;

EID: 84884414183     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283632ea1     Document Type: Article

References (40)

1. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, Trabbatoni D, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001; 79:29-36.
2. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731-1741.
3. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir ImmuneDefic Syndr 2002; 30:413-420.
4. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
5. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871-875.
6. Pastori C, Barassi C, Piconi S, Longhi R, Villa ML, Siccardi AG, et al. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents 2000; 14:15-21.
7. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
8. Wright A, Lamm ME, Huang YT. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol 2008; 82:11526-11535.
9. Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 1997; 13:1179-1185.
10. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001; 184:1412-1422.
11. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9:277-287.
12. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ly N, et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006; 42:412-419.
13. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001; 15:431-432.
14. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23-29.
15. Matsuda S, Noda M. Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41. Microbiol Immunol 2000; 44:923-929.
16. Vincent N, Malvoisin E, Pozzetto B, Lucht F, Genin C. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients. AIDS 2004; 18:37-43.
17. Moja P, Tranchat C, Tchou I, Pozzetto B, Lucht F, Desgranges C, et al. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. J Infect Dis 2000; 181:1607-1613.
18. Nishiyama Y, Karle S, Planque S, Taguchi H, Paul S. Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit. Mol Immunol 2007; 44:2707-2718.
19. Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, et al. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. J Immunol 2012; 189:5367-5381.
20. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, et al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010; 24:875-884.
21. Granados-Gonzalez V, Piedrahita LD, Martinez-Gutierrez M, Lawrence P, Saoudin H, Zapata X, et al. Neutralizing interclade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts. AIDS 2009; 23:2219-2222.
22. Granados-Gonzalez V, Piedrahita LD, Martinez M, Genin C, Riffard S, Urcuqui-Inchima S. Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies. Enferm Infecc Microbiol Clin 2009; 27:523-530.
23. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
24. Denner J, Eschricht M, Lauck M, Semaan M, Schlaermann P, Ryu H, et al. Modulation of cytokine release and gene expression by the immunosuppressive domain of gp41 of HIV-1. PLoS One 2013; 8:e55199.
25. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoproteinmediated membrane fusion. J Virol 1999; 73:6089-6092.
26. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, et al. Structure and mechanistic analysis of the antihuman immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78:10724-10737.
27. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Antihuman immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252-1261.
28. Zwick MB, Burton DR. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 2007; 5:608-624.
29. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-412.
30. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001; 166:6257-6265.
31. Dawood R, Benjelloun F, Pin JJ, Kone A, Chanut B, Jospin F, et al. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex. AIDS 2013; 27:717-730.
32. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011; 4:603-611.
33. Paul A, Antony M, Mathai J, Appukuttan PS. High polymeric IgA content facilitates recognition of microbial polysaccharidenatural serum antibody immune complexes by immobilized human galectin-1. Immunol Lett 2011; 136:55-60.
34. Vincent N, Kone A, Chanut B, Lucht F, Genin C, Malvoisin E. Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. AIDS 2008; 22:2075-2085.
35. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999; 73:2469-2480.
36. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
37. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M, et al. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009; 23:161-175.
38. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14:1117-1122.
39. Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, et al. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 2011; 27:469-486.
40. Choi RY, Levinson P, Guthrie BL, Lohman-Payne B, Bosire R, Liu AY, et al. Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 2012; 26:2155-2163.